Eziclen Drug Utilisation in Real Life Setting (DUS-BLI800)

Ipsen

Status: Completed

Conditions: Bowel Cleansing

Treatments: Drug: Eziclen®/Izinova®

Study type: Observational

Funder types: Industry

Identifiers

NCT02630680

8-79-58800-001

EUPAS9361 (Registry Identifier)

Details and patient eligibility

About

The purpose of the study is to assess Eziclen/Izinova drug utilisation in the real life setting in a representative sample of the European target population.

Enrollment: 1,286 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation.
• Patient having provided written informed consent.

Exclusion criteria

• Patient not eligible for a prescription of BLI800 (Eziclen®/Izinova®) as a cleansing bowel preparation in accordance with the marketing authorisation. Specifically, patients in whom there is a contraindication for use of this product, including patients with congestive heart failure, severe renal insufficiency of active inflammatory bowel disease, are not eligible for inclusion in this study.
• Patient being prescribed a cleansing bowel preparation other than BLI800 (Eziclen®/Izinova®).

Trial design

1,286 participants in 1 patient group

Colorectal diseases patients

Treatment:

Drug: Eziclen®/Izinova®